Jump to content

Lindy Durrant: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
c/e
Line 1: Line 1:
{{Short description|British immunologist}}
{{Short description|British immunologist}}
{{Orphan|date=April 2022}}
{{Orphan|date=April 2022}}

{{Infobox scientist
{{Infobox scientist
| name = Lindy Gillian Durrant
| name = Lindy Gillian Durrant
Line 7: Line 6:
| alma_mater = [[University of Manchester]] <br> [[Paterson Institute for Cancer Research]]
| alma_mater = [[University of Manchester]] <br> [[Paterson Institute for Cancer Research]]
}}
}}
⚫
'''Lindy Durrant''' is a British immunologist who is Professor of Cancer Immunotherapy and Chief Scientific Office of Scancell Ltd. She developed a panel of [[Monoclonal antibody|monoclonal antibodies]], recognised tumour associated glycans, and pioneered a novel antibody engineering technology to enhance the avidity of monoclonal antibodies and new antibody engineering technologies. Her research has been used for anti-glycan monoclonal antibodies.

⚫
'''Lindy Durrant''' is a British immunologist, Professor of Cancer Immunotherapy and Chief Scientific Office of Scancell Ltd. She developed a panel of [[Monoclonal antibody|monoclonal antibodies]] recognised tumour associated glycans, pioneered a novel antibody engineering technology to enhance the avidity of [[Monoclonal antibody|monoclonal antibodies]] and new antibody engineering technologies. Her research has been used for anti-glycan [[Monoclonal antibody|monoclonal antibodies]].


== Early life and education ==
== Early life and education ==
{{no refs|section|date=April 2022}}
{{no refs|section|date=April 2022}}
Durrant was an undergraduate student at the [[University of Manchester]], where she studied biochemistry. She moved to the medical school as a graduate student, where she started working on cancer chemotherapy at the [[Paterson Institute for Cancer Research]]. After earning her doctorate she was appointed as a postdoctoral scholar.
Durrant was an undergraduate student at the [[University of Manchester]], where she studied biochemistry. She moved to the medical school, where she started working on cancer chemotherapy at the [[Paterson Institute for Cancer Research]]. After earning her doctorate, she was appointed as a postdoctoral scholar.


== Research and career ==
== Research and career ==
In 1981 Durrant joined the [[University of Nottingham]]. Durrant founded the company Scancell in 1997.<ref>{{Cite web |title=COMPANY - Scancell |url=https://www.scancell.co.uk/company |access-date=2022-04-28 |website=www.scancell.co.uk}}</ref><ref>{{Cite web |date=2022-01-01 |title=From flying taxis to painless vaccines: seven businesses to watch this year |url=https://www.theguardian.com/business/2022/jan/01/from-flying-taxis-to-painless-vaccines-seven-businesses-to-watch-this-year |access-date=2022-04-29 |website=the Guardian |language=en}}</ref> Scancell have developed a [[DNA vaccine]] platform that can stimulate [[T cell]]s which kills tumour cells. Durrant has developed two vaccine platforms, ImmunoBody<sup>TM</sup> and Moditope<sup>TM</sup>. These vaccines induce killer [[CD8]] [[T cell]]s and [[Cytotoxicity|cytotoxic]] [[CD4+ T cells and antitumor immunity|CD4 T cells]]. ImmunoBody<sup>TM</sup> has been successfully used to treat patients with melanoma.
In 1981, Durrant joined the [[University of Nottingham]]. Durrant founded the company Scancell in 1997.<ref>{{Cite web |title=COMPANY - Scancell |url=https://www.scancell.co.uk/company |access-date=2022-04-28 |website=www.scancell.co.uk}}</ref><ref>{{Cite web |date=2022-01-01 |title=From flying taxis to painless vaccines: seven businesses to watch this year |url=https://www.theguardian.com/business/2022/jan/01/from-flying-taxis-to-painless-vaccines-seven-businesses-to-watch-this-year |access-date=2022-04-29 |website=the Guardian |language=en}}</ref> Scancell has developed a [[DNA vaccine]] platform that can stimulate [[T cell]]s which kills tumour cells. Durrant has developed two vaccine platforms, ImmunoBody<sup>TM</sup> and Moditope<sup>TM</sup>. These vaccines induce killer [[CD8]] T cells and [[Cytotoxicity|cytotoxic]] [[CD4+ T cells and antitumor immunity|CD4 T cells]]. ImmunoBody<sup>TM</sup> has been successfully used to treat patients with melanoma.{{cn}}


Scancell created two [[COVID-19 vaccine]]s,<ref>{{Cite web |last=Locker |first=Joseph |date=2020-04-26 |title=Nottingham scientists identify parts of coronavirus which may lead to vaccine |url=https://www.nottinghampost.com/news/nottingham-news/scientists-nottingham-universities-identify-parts-4079052 |access-date=2022-04-29 |website=NottinghamshireLive |language=en}}</ref> which induce antibody and T-cell responses against [[severe acute respiratory syndrome coronavirus 2]] and its variants.<ref name=":0">{{Cite web |date=2021-12-11 |title=As Covid mutates, the vaccine makers are adapting too |url=https://www.theguardian.com/business/2021/dec/11/as-covid-mutates-the-vaccine-makers-are-adapting-too |access-date=2022-04-29 |website=the Guardian |language=en}}</ref><ref>{{Cite web |title=COVID-19: New vaccine in development has 'insurance' against coronavirus mutations |url=https://news.sky.com/story/covid-19-new-vaccine-in-development-has-insurance-against-virus-mutations-12217119 |access-date=2022-04-29 |website=Sky News |language=en}}</ref><ref>{{Cite web |date=2021-02-14 |title=British scientists to trial new Covid vaccine with 'insurance' against mutant variants |url=https://inews.co.uk/news/uk/british-scientists-trial-new-covid-vaccine-mutant-variants-871438 |access-date=2022-04-29 |website=inews.co.uk |language=en}}</ref> It is expected that vaccines that induce a strong T-cell response would achieve longer lasting immunity. The vaccines, which were supported by the [[University of Nottingham]] and [[Nottingham Trent University]], underwent clinical trials in 2021.<ref name=":0" /> They are administered via spring-powered injectors which deliver a stream of fluid.<ref name=":0" />
Scancell created two [[COVID-19 vaccine]]s,<ref>{{Cite web |last=Locker |first=Joseph |date=2020-04-26 |title=Nottingham scientists identify parts of coronavirus which may lead to vaccine |url=https://www.nottinghampost.com/news/nottingham-news/scientists-nottingham-universities-identify-parts-4079052 |access-date=2022-04-29 |website=NottinghamshireLive |language=en}}</ref> which induce antibody and T-cell responses against [[severe acute respiratory syndrome coronavirus 2]] and its variants.<ref name=":0">{{Cite web |date=2021-12-11 |title=As Covid mutates, the vaccine makers are adapting too |url=https://www.theguardian.com/business/2021/dec/11/as-covid-mutates-the-vaccine-makers-are-adapting-too |access-date=2022-04-29 |website=the Guardian |language=en}}</ref><ref>{{Cite web |title=COVID-19: New vaccine in development has 'insurance' against coronavirus mutations |url=https://news.sky.com/story/covid-19-new-vaccine-in-development-has-insurance-against-virus-mutations-12217119 |access-date=2022-04-29 |website=Sky News |language=en}}</ref><ref>{{Cite web |date=2021-02-14 |title=British scientists to trial new Covid vaccine with 'insurance' against mutant variants |url=https://inews.co.uk/news/uk/british-scientists-trial-new-covid-vaccine-mutant-variants-871438 |access-date=2022-04-29 |website=inews.co.uk |language=en}}</ref> It is expected that vaccines that induce a strong T-cell response would achieve longer lasting immunity.{{cn}} The vaccines, which were supported by the [[University of Nottingham]] and [[Nottingham Trent University]], underwent clinical trials in 2021.<ref name=":0" /> They are administered via spring-powered injectors which deliver a stream of fluid.<ref name=":0" />

⚫
== Awards and honour ==


⚫
== Awards and honours ==
* 2019 Swedish Society of Oncology Waldenstrom Prize<ref>{{Cite web |title=Professor Lindy Durrant receives Waldenstr̦m award РCompany Announcement - FT.com |url=https://markets.ft.com/data/announce/full?dockey=1323-14010019-595GB7IT3HL5BSB8O4Q02JJMAD |access-date=2022-04-28 |website=markets.ft.com}}</ref>
* 2019 Swedish Society of Oncology Waldenstrom Prize<ref>{{Cite web |title=Professor Lindy Durrant receives Waldenstr̦m award РCompany Announcement - FT.com |url=https://markets.ft.com/data/announce/full?dockey=1323-14010019-595GB7IT3HL5BSB8O4Q02JJMAD |access-date=2022-04-28 |website=markets.ft.com}}</ref>


== Select publications ==
== Selected publications ==

* {{Cite Q|Q53851520}}
* {{Cite Q|Q53851520}}
* {{Cite Q|Q54539424}}
* {{Cite Q|Q54539424}}
Line 33: Line 29:


{{Authority control}}
{{Authority control}}
{{DEFAULTSORT:Durrant, Lindy}}
[[Category:Living people]]
[[Category:Living people]]
[[Category:Alumni of the University of Manchester]]
[[Category:Alumni of the University of Manchester]]

Revision as of 11:36, 30 April 2022

Lindy Gillian Durrant
Alma materUniversity of Manchester
Paterson Institute for Cancer Research
Scientific career
InstitutionsUniversity of Nottingham
Scancell Ltd

Lindy Durrant is a British immunologist who is Professor of Cancer Immunotherapy and Chief Scientific Office of Scancell Ltd. She developed a panel of monoclonal antibodies, recognised tumour associated glycans, and pioneered a novel antibody engineering technology to enhance the avidity of monoclonal antibodies and new antibody engineering technologies. Her research has been used for anti-glycan monoclonal antibodies.

Early life and education

Durrant was an undergraduate student at the University of Manchester, where she studied biochemistry. She moved to the medical school, where she started working on cancer chemotherapy at the Paterson Institute for Cancer Research. After earning her doctorate, she was appointed as a postdoctoral scholar.

Research and career

In 1981, Durrant joined the University of Nottingham. Durrant founded the company Scancell in 1997.[1][2] Scancell has developed a DNA vaccine platform that can stimulate T cells which kills tumour cells. Durrant has developed two vaccine platforms, ImmunoBodyTM and ModitopeTM. These vaccines induce killer CD8 T cells and cytotoxic CD4 T cells. ImmunoBodyTM has been successfully used to treat patients with melanoma.[citation needed]

Scancell created two COVID-19 vaccines,[3] which induce antibody and T-cell responses against severe acute respiratory syndrome coronavirus 2 and its variants.[4][5][6] It is expected that vaccines that induce a strong T-cell response would achieve longer lasting immunity.[citation needed] The vaccines, which were supported by the University of Nottingham and Nottingham Trent University, underwent clinical trials in 2021.[4] They are administered via spring-powered injectors which deliver a stream of fluid.[4]

Awards and honours

  • 2019 Swedish Society of Oncology Waldenstrom Prize[7]

Selected publications

  • Nicholas F S Watson; Judith M. Ramage; Zahra Madjd; Ian Spendlove; Ian Ellis; John H Scholefield; Lindy G Durrant (1 January 2006). "Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis". International Journal of Cancer. 118 (1): 6–10. doi:10.1002/IJC.21303. ISSN 0020-7136. PMID 16003753. Wikidata Q53851520.
  • Ekaterina S. Jordanova; Ekaterina S. Jordanova; Arko Gorter; et al. (1 April 2008). "Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?". Clinical Cancer Research. 14 (7): 2028–2035. doi:10.1158/1078-0432.CCR-07-4554. ISSN 1078-0432. PMID 18381941. Wikidata Q54539424.
  • Nicholas F S Watson; Ian Spendlove; Zahra Madjd; Roger McGilvray; Andrew R Green; Ian O Ellis; John H Scholefield; Lindy G Durrant (1 March 2006). "Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients". International Journal of Cancer. 118 (6): 1445–1452. doi:10.1002/IJC.21510. ISSN 0020-7136. PMID 16184547. Wikidata Q50753300.

References

  1. ^ "COMPANY - Scancell". www.scancell.co.uk. Retrieved 2022-04-28.
  2. ^ "From flying taxis to painless vaccines: seven businesses to watch this year". the Guardian. 2022-01-01. Retrieved 2022-04-29.
  3. ^ Locker, Joseph (2020-04-26). "Nottingham scientists identify parts of coronavirus which may lead to vaccine". NottinghamshireLive. Retrieved 2022-04-29.
  4. ^ a b c "As Covid mutates, the vaccine makers are adapting too". the Guardian. 2021-12-11. Retrieved 2022-04-29.
  5. ^ "COVID-19: New vaccine in development has 'insurance' against coronavirus mutations". Sky News. Retrieved 2022-04-29.
  6. ^ "British scientists to trial new Covid vaccine with 'insurance' against mutant variants". inews.co.uk. 2021-02-14. Retrieved 2022-04-29.
  7. ^ "Professor Lindy Durrant receives Waldenstr̦m award РCompany Announcement - FT.com". markets.ft.com. Retrieved 2022-04-28.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Lindy_Durrant&oldid=1085407808"